Alerts will be sent to your verified email
Verify EmailAMRAPLIN
|
Amrapali Industries
|
Novelix Pharma
|
Aviva Industries
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
3.36 % | 0.0 | 0.07 % |
|
5yr average Equity Multiplier
|
5.15 | 1.26 | 1.29 |
|
5yr Average Asset Turnover Ratio
|
174.43 | 0.84 | 0.08 |
|
5yr Avg Net Profit Margin
|
0.0 | -14.11 % | -54.19 % |
|
Price to Book
|
4.4 | 26.26 | 2.64 |
|
P/E
|
16.06 | 74.05 | 105.73 |
|
5yr Avg Cash Conversion Cycle
|
0.31 Days | 29.1 Days | 1390.57 Days |
|
Inventory Days
|
0.29 Days | 34.04 Days | 0.74 Days |
|
Days Receivable
|
0.0 | 55.38 Days | 2188.29 Days |
|
Days Payable
|
0.07 Days | 55.7 Days | 183.45 Days |
|
5yr Average Interest Coverage Ratio
|
1.31 | -17.77 | 1.24 |
|
5yr Avg ROCE
|
17.8 % | -15.4 % | -0.49 % |
|
5yr Avg Operating Profit Margin
|
0.01 % | -16.49 % | -54.26 % |
|
5 yr average Debt to Equity
|
2.09 | 0.05 | 0.2 |
|
5yr CAGR Net Profit
|
17.46 % | 35.78 % | n/a |
|
5yr Average Return on Assets
|
0.74 % | -13.36 % | -0.52 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
73.43 % | 50.57 % | 3.01 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -16.35 % | -62.29 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Amrapali Industries
|
Novelix Pharma
|
Aviva Industries
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|